カテゴリ： GlobalData, カナダ, 企業調査

Intellipharmaceutics International Inc (IPCI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Intellipharmaceutics International Inc (IPCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9811
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：70
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral solid dosage drugs based on its proprietary technology, Hypermatrix, a multidimensional controlled-release drug delivery platform. Its products and product candidates are used for the treatment of various indications, including neuropathic pain, attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, major depressive disorder, hypertension, type 2 diabetes, and chronic angina. It offers a comprehensive range of services, including pre-formulation studies, design, and development through to regulatory approval. Intellipharmaceutics’ is headquartered in Toronto, Ontario, Canada.

Intellipharmaceutics International Inc (IPCI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Equity Offering 13
Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13
Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15
Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16
Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17
Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19
Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 22
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 23
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 24
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 25
Debt Offering 27
Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 28
Intellipharmaceutics International Inc – Key Competitors 29
Intellipharmaceutics International Inc – Key Employees 30
Intellipharmaceutics International Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Oct 15, 2018: Intellipharmaceutics announces third quarter 2018 results 32
Jul 16, 2018: Intellipharmaceutics reports second quarter 2018 results 35
Apr 16, 2018: Intellipharmaceutics Reports First Quarter 2018 Results 38
Oct 10, 2017: Intellipharmaceutics Announces Third Quarter 2017 Results 41
Jul 11, 2017: Intellipharmaceutics Announces Second Quarter 2017 Results 43
Apr 11, 2017: Intellipharmaceutics Announces First Quarter 2017 Results 45
Feb 10, 2017: Intellipharmaceutics Announces 2016 Year End Results 48
Corporate Communications 51
Nov 05, 2018: Intellipharmaceutics: Resignation of Chief Financial Officer 51
Jun 08, 2018: Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ 52
Apr 27, 2018: Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination 53
Sep 01, 2017: Intellipharmaceutics Appoints New Chief Financial Officer 54
Aug 08, 2017: Intellipharmaceutics Announces Resignation of CFO 55
Legal and Regulatory 56
May 26, 2017: Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement 56
Product News 57
09/05/2017: Intellipharmaceutics Provides Operational Update 57
07/31/2017: Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit 59
05/08/2018: Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER 60
Product Approvals 61
Feb 09, 2018: Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program 61
Sep 25, 2017: Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista NDA 62
Jul 26, 2017: Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 63
Jun 30, 2017: Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 64
Feb 02, 2017: Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 65
Other Significant Developments 66
Jan 24, 2018: Intellipharmaceutics Provides Operational Update 66
Mar 16, 2017: Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI” 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13
Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15
Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16
Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17
Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19
Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 22
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 23
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 24
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 25
Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 28
Intellipharmaceutics International Inc, Key Competitors 29
Intellipharmaceutics International Inc, Key Employees 30
Intellipharmaceutics International Inc, Subsidiaries 31

List of Figures
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Intellipharmaceutics International Inc (IPCI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Maxim Power Corp. (MXG)：電力：M&Aディール及び事業提携情報
    Summary Maxim Power Corp. (Maxim) is an independent power producing corporation that acquires, develops, owns and operates power generation facilities and sells electricity and heat. The corporation generates electricity using various fuel sources including coal, natural gas, and wind, nuclear, hydr …
  • HOK Group, Inc.：企業の戦略・SWOT・財務情報
    HOK Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary HOK Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Aevi Genomic Medicine Inc (GNMX)-製薬・医療分野：企業M&A・提携分析
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company’s pipeline products include AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamaterg …
  • Odonate Therapeutics Inc (ODT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Odonate Therapeutics Inc (Odonate), formerly Odonate Therapeutics LLC, is a pharmaceutical company that develops medicines for the treatment of cancer. The company provides product candidate, tesetaxel which is a novel orally administered taxane used for the treatment of advanced and metasta …
  • The Bank Of East Asia, Limited
    The Bank Of East Asia, Limited - Strategy, SWOT and Corporate Finance Report Summary The Bank Of East Asia, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • National Fuel Gas Co (NFG)：企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Innospec Inc. (IOSP)-石油・ガス分野：企業M&A・提携分析
    Summary Innospec Inc. (Innospec) is a specialty chemicals company. It blends, manufactures and supplies fuel additives and other specialty chemicals. Innospec’s product portfolio includes detergents, cold flow improvers, lubricity improvers, corrosion inhibitors, conductivity improvers, wax modifier …
  • Chevron Corp (CVX)：企業の財務・戦略的SWOT分析
    Chevron Corp (CVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Westgold Resources Ltd (WGX)：企業の財務・戦略的SWOT分析
    Westgold Resources Ltd (WGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Cyclopharm Ltd (CYC)：医療機器：M&Aディール及び事業提携情報
    Summary Cyclopharm Ltd (Cyclopharm) is a radiopharmaceutical company that manufactures medical and healthcare equipment and components in the nuclear medicine business. The company’s products include Technegas, a lung imaging device used to diagnose the presence of blood clots in the lungs; and posi …
  • Option Care Health Inc (OPCH)：企業の財務・戦略的SWOT分析
    Option Care Health Inc (OPCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • ICON Plc (ICLR)：企業の財務・戦略的SWOT分析
    ICON Plc (ICLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Dova Pharmaceuticals Inc (DOVA)-製薬・医療分野：企業M&A・提携分析
    Summary Dova Pharmaceuticals Inc (Dova) is a clinical-stage pharmaceutical company that develops therapies for the treatment of orphan diseases. The company’s lead candidate, Avatrombopag (AVA), a novel, oral thrombopoietin receptor agonist, is under development for the treatment of thrombocytopenia …
  • Intuity Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Intuity Medical Inc (Intuity Medical), formerly Rosedale Medical is a medical device company that designs and develops medical devices to monitor diabetes. The company offers products such as POGO, an automatic blood glucose monitoring system; and Patterns, a web based data management system …
  • PT Supreme Cable Manufacturing & Commerce Tbk (SCCO)：企業の財務・戦略的SWOT分析
    PT Supreme Cable Manufacturing & Commerce Tbk (SCCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • TFS International AB：製薬・医療：M&Aディール及び事業提携情報
    Summary TFS International AB (TFS International) is a contract research organization that provides clinical development solutions. The organization through its business areas, TFS Develop and TFS People, provides various services worldwide including clinical development planning, regulatory affairs, …
  • Fresenius Medical Care AG & Co KGaA (FMS)：医療機器：M&Aディール及び事業提携情報
    Summary Fresenius Medical Care AG & Co KGaA (Fresenius Medical), a subsidiary of Fresenius SE & Co KGaA, is an integrated dialysis company. It is one of the largest kidney dialysis companies in the world. It provides dialysis care services and products to individuals with chronic kidney failure. It …
  • Greenply Industries Ltd：企業の戦略・SWOT・財務情報
    Greenply Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Greenply Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Vista Gold Corp.：企業の戦略・SWOT・財務情報
    Vista Gold Corp. - Strategy, SWOT and Corporate Finance Report Summary Vista Gold Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tel Aviv Sourasky Medical Center：製薬・医療：M&Aディール及び事業提携情報
    Summary Tel Aviv Sourasky Medical Center (Sourasky Medical) is an academic medical center that provides patient-centered care, research and education services. The center offers services in the areas of cardiology, dermatology, gastroenterology, general surgery, genetics, emergency medicine, rheumat …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆